logo

For the Inventor, By the Inventor

Epalinges, Switzerland

Adc Therapeutics Sa


USPTO Granted Patents = 21

% Expired Patents = 14.3



Trademarks = 8

Forward Citations = 37

Loading Chart...
Loading Chart...

14 inventors (with patents filed for the assignee):

goldMedal Patricius Hendrikus Cornelis Van Berkel (13 out of 24 patents)

silverMedal Philip Wilson Howard (8 out of 92 patents)

bronzeMedal Jay Marshall Feingold (4 out of 4 patents)

4.  Gilles Bernard Tremblay (4 out of 29 patents)

5.  Mario Filion (4 out of 26 patents)

6.  Traian Sulea (3 out of 34 patents)

7.  Anna N Moraitis (3 out of 6 patents)

8.  John Hartley (3 out of 4 patents)

9.  Jens Wuerthner (3 out of 3 patents)

10.  David Rodney Ungar (2 out of 2 patents)

11.  Francesca Zammarchi (2 out of 2 patents)

12.  Patricius Henrikus Cornelis Van Berkel (1 out of 2 patents)

13.  Lisa Skelton (1 out of 1 patent)

14.  Francois Bertelli (1 out of 1 patent)

15.  Francesco Bertoni (7 patents)


21 patents:

1. 11976122 - Anti-IL13Rα2 antibodies (2024-05-07),
2. 11938192 - Dosage regimes for the administration of an anti-CD19 ADC (2024-03-26),
3. 11813335 - Pyrrolobenzodiazepine-antibody conjugates (2023-11-14),
4. 11702473 - Site-specific antibody-drug conjugates (2023-07-18),
5. 11690918 - Pyrrolobenzodiazepine-anti-CD22 antibody conjugates (2023-07-04),
6. 11596696 - Combination therapy with an anti-CD25 antibody-drug conjugate (2023-03-07),
7. 11426467 - Dosage regimes for the administration of an anti-CD25 ADC (2022-08-30),
8. 11384098 - Pyrrolobenzodiazepine-antibody conjugates (2022-07-12),
9. 11318211 - Dosage regimes for the administration of an anti-CD19 ADC (2022-05-03),
10. 11160872 - Pyrrolobenzodiazepine-antibody conjugates (2021-11-02),
11. 11084872 - Method for treating breast cancer (2021-08-10),
12. 10799596 - Pyrrolobenzodiazepine-antibody conjugates (2020-10-13),
13. 10780096 - Pyrrolobenzodiazepine-antibody conjugates (2020-09-22),
14. 10722594 - Pyrrolobenzodiazepine-anti-CD22 antibody conjugates (2020-07-28),
15. 10597450 - Antibodies against kidney associated antigen 1 and antigen binding fragments thereof (2020-03-24),
Company Overview
Adc Therapeutics SA is a biotechnology company based in Epalinges, Switzerland, focused on the development of innovative antibody-drug conjugates (ADCs) for the treatment of cancer. The company specializes in leveraging its proprietary technology to create targeted therapies that combine the specificity of antibodies with the potency of cytotoxic drugs. Adc Therapeutics aims to address unmet medical needs in oncology, advancing its research and development efforts to improve patient outcomes in various hematological malignancies and solid tumors.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

21 Patents

#2 in Epalinges

#592 in Switzerland

#29,961 in the World

Epalinges, CH
Epalinges, Switzerland

Adc Therapeutics Sa

Forward Citations = 37

14 inventors:

goldMedal Patricius Hendrikus Cornelis Van Berkel (13 out of 24 patents)

silverMedal Philip Wilson Howard (8 out of 92 patents)

bronzeMedal Jay Marshall Feingold (4 out of 4 patents)

4.  Gilles Bernard Tremblay (4 out of 29 patents)

5.  Mario Filion (4 out of 26 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Adc Therapeutics Sa. Retrieved from https://idiyas.com/company/adc-therapeutics-sa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…